Jaume Reventós

12.4k total citations
141 papers, 4.7k citations indexed

About

Jaume Reventós is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Jaume Reventós has authored 141 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Molecular Biology, 44 papers in Pulmonary and Respiratory Medicine and 32 papers in Genetics. Recurrent topics in Jaume Reventós's work include Prostate Cancer Treatment and Research (30 papers), Endometrial and Cervical Cancer Treatments (21 papers) and Hormonal and reproductive studies (20 papers). Jaume Reventós is often cited by papers focused on Prostate Cancer Treatment and Research (30 papers), Endometrial and Cervical Cancer Treatments (21 papers) and Hormonal and reproductive studies (20 papers). Jaume Reventós collaborates with scholars based in Spain, United States and Palestinian Territory. Jaume Reventós's co-authors include Juan Moróte, Antonio Gil‐Moreno, Francina Munell, Miguel Abal, Jordi Xercavins, Marina Rigau, Eva Colás, Andreas Doll, Enrique Trilla and Simó Schwartz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jaume Reventós

137 papers receiving 4.6k citations

Peers

Jaume Reventós
Robert D. Koos United States
Nam Keun Kim South Korea
Louis Dubeau United States
Arto Orpana Finland
Katherine F. Roby United States
Jaume Reventós
Citations per year, relative to Jaume Reventós Jaume Reventós (= 1×) peers Annemarie A. Donjacour

Countries citing papers authored by Jaume Reventós

Since Specialization
Citations

This map shows the geographic impact of Jaume Reventós's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaume Reventós with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaume Reventós more than expected).

Fields of papers citing papers by Jaume Reventós

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaume Reventós. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaume Reventós. The network helps show where Jaume Reventós may publish in the future.

Co-authorship network of co-authors of Jaume Reventós

This figure shows the co-authorship network connecting the top 25 collaborators of Jaume Reventós. A scholar is included among the top collaborators of Jaume Reventós based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaume Reventós. Jaume Reventós is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oliván, Mireia, Marta García, Marc Guiu, et al.. (2021). Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples. Cancers. 13(24). 6202–6202. 11 indexed citations
2.
Martínez-García, Elena, Antoine Lesur, Laura Devis, et al.. (2017). Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment. Clinical Cancer Research. 23(21). 6458–6467. 50 indexed citations
3.
Dowdy, Tyrone, Kirandeep Gill, Cristian P. Moiola, et al.. (2017). Metabolomic and Lipidomic Profiling Identifies The Role of the RNA Editing Pathway in Endometrial Carcinogenesis. Scientific Reports. 7(1). 8803–8803. 35 indexed citations
4.
Moróte, Juan, A. Celma, Jacques Planas, et al.. (2014). Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness. International Journal of Molecular Sciences. 15(8). 13615–13623. 25 indexed citations
5.
Rigau, Marina, Mireia Oliván, Marta García, et al.. (2013). The Present and Future of Prostate Cancer Urine Biomarkers. International Journal of Molecular Sciences. 14(6). 12620–12649. 56 indexed citations
6.
Majem, Blanca, Josep Castellví, Sílvia Cabrera, et al.. (2012). Analysis of Gene Expression Regulated by the ETV5 Transcription Factor in OV90 Ovarian Cancer Cells Identifies FOXM1 Overexpression in Ovarian Cancer. Molecular Cancer Research. 10(7). 914–924. 24 indexed citations
7.
Muinelo‐Romay, Laura, Eva Colás, Jorge Barbazán, et al.. (2011). High-Risk Endometrial Carcinoma Profiling Identifies TGF-β1 as a Key Factor in the Initiation of Tumor Invasion. Molecular Cancer Therapeutics. 10(8). 1357–1366. 35 indexed citations
8.
Moróte, Juan, Marina Rigau, Marta García, et al.. (2010). Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia. World Journal of Urology. 28(6). 677–680. 23 indexed citations
9.
Guillem‐Marti, Jordi, Ramón Díaz, Maite Quiles, et al.. (2008). MMPs/TIMPs and inflammatory signalling de‐regulation in human incisional hernia tissues. Journal of Cellular and Molecular Medicine. 13(11-12). 4432–4443. 25 indexed citations
10.
Monge, Marta, Eva Colás, Andreas Doll, et al.. (2007). ERM/ETV5 Up-regulation Plays a Role during Myometrial Infiltration through Matrix Metalloproteinase-2 Activation in Endometrial Cancer. Cancer Research. 67(14). 6753–6759. 47 indexed citations
11.
Abal, Miguel, Antònia Obrador‐Hevia, Klaus‐Peter Janssen, et al.. (2007). APC Inactivation Associates With Abnormal Mitosis Completion and Concomitant BUB1B/MAD2L1 Up-Regulation. Gastroenterology. 132(7). 2448–2458. 30 indexed citations
12.
Doll, Andreas, Miguel Abal, Marina Rigau, et al.. (2007). Novel molecular profiles of endometrial cancer—new light through old windows. The Journal of Steroid Biochemistry and Molecular Biology. 108(3-5). 221–229. 163 indexed citations
13.
Mogas, T., Teresa Baró, Rosa M. Rabanal, et al.. (2006). Expression of Androgen, Oestrogen α and β, and Progesterone Receptors in the Canine Prostate: Differences between Normal, Inflamed, Hyperplastic and Neoplastic Glands. Journal of Comparative Pathology. 136(1). 1–8. 21 indexed citations
14.
Santamaría, Anna, Pedro L. Fernández, Xavier Farré, et al.. (2003). PTOV-1, a Novel Protein Overexpressed in Prostate Cancer, Shuttles between the Cytoplasm and the Nucleus and Promotes Entry into the S Phase of the Cell Division Cycle. American Journal Of Pathology. 162(3). 897–905. 45 indexed citations
15.
Esteller, Manel, et al.. (1999). Endometrial Carcinoma in Tamoxifen-Treated Breast Cancer Patient. International Journal of Gynecological Pathology. 18(4). 387–391. 4 indexed citations
17.
Schwartz, Simó, et al.. (1998). Over-expression of epidermal growth factor receptor and c-erbB2/neu but not ofint-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR. International Journal of Cancer. 76(4). 464–467. 16 indexed citations
18.
Larriba, Sara, et al.. (1995). Androgen binding protein is tissue-specifically expressed and biologically active in transgenic mice. The Journal of Steroid Biochemistry and Molecular Biology. 53(1-6). 573–578. 23 indexed citations
19.
Reventós, Jaume, et al.. (1979). Paragangliomes du médiastin.. Annales de Chirurgie. 33(3). 1 indexed citations
20.
Reventós, Jaume, et al.. (1973). Early and Late Effects of Pulmonary Denervation in the Dog. European Surgical Research. 5(2). 135–145. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026